Cite this article as: Tian L, Cai P-Q, Cui C-Y, Mo Y-X, Gong X, Fan W. Reactive thymic hyperplasia following chemotherapy for children with lymphoma: computed tomography may be able to provide valuable information to avoid over-treatment. Eur J Cardiothorac Surg 2015;47:883-9. Reactive thymic hyperplasia following chemotherapy for children with lymphoma: computed tomography may be able to provide valuable information to avoid over-treatment Abstract OBJECTIVES: To analyse the clinical and computed tomography (CT) findings related to reactive thymic hyperplasia in order to improve the recognition of this phenomenon and avert over-treatment.
INTRODUCTION
The thymus is the most sensitive organ in the body in terms of its atrophic reaction to stress factors, such as starvation, fever and chemotherapy. It can regrow to its original size after atrophy or, at times, rebound to a larger size [1, 2] . Reactive thymic hyperplasia, also known as thymic rebound, is a well-documented phenomenon in children receiving chemotherapy for various malignancies [3] [4] [5] [6] . However, a new or recurrent mediastinal mass in children treated for malignant disease often presents a diagnostic dilemma, and is usually misdiagnosed as tumour recurrence or metastasis and thereby unnecessarily over-treated. How can this medical error be avoided? Perhaps an image examination, such as computed tomography (CT) scan, can provide some valuable information with regard to the differential diagnosis of hyperplastic thymus from mediastinal tumours. This study aimed to analyse the
MATERIALS AND METHODS

Patient population
Institutional review board approval and written informed consent were obtained for this study. Between December 2005 and December 2012, 341 children with pathologically confirmed lymphoma were treated in our hospital. The inclusion criteria of this retrospective study were as follows: (i) the mediastinal mass detected at initial diagnosis achieved CR after chemotherapy. A recurrent mass occurred in the anterior-superior mediastinum during follow-up or maintenance treatment, which was closely followed up without any intervening measures. (ii) The mediastinum was disease-free at initial diagnosis, and a new mass occurred in the anterior-superior mediastinum during treatment or the follow-up period, which was closely followed up without any intervening measures. (iii) The recurrent or newly developed mediastinal masses shrank naturally or remained unchanged with long-term follow-up. Finally, 52 children (43 boys and 9 girls; median age 8 years, range 2-14 years) were enrolled. The clinical features of the 52 children are summarized in Table 1 .
Computed tomography scanning
All of the patients underwent a baseline CT scan at initial diagnosis and a follow-up CT examination after induction chemotherapy or for suspicion of tumour recurrence or metastasis. Each patient was re-examined by CT once every 2 months.
The CT scans were performed with a Brilliance TM16 (Philips Medical Systems, Best, Netherlands) or a Toshiba Aquilion TM64 (Toshiba Medical Systems, Otawara, Japan) helical CT system. The main imaging parameters were as follows: 5-mm section thickness reconstructions, 25-cm field of view, 120-kV tube voltage, 250-300-mA current and a 512 × 512 matrix. An intravenous bolus dose (1.5-2.0 ml/kg body weight) of non-ionic iodinated contrast agent (iopromide; Ultravist, Schering, Berlin, Germany) was administered at a rate of 1 ml/s.
Treatment
All of the children received standard chemotherapy. Patients with Hodgkin's disease (HD) were given an ABVD regimen (amycin, bleomycin, vincristine and dacarbazine) [7, 8] . Patients with diffuse large B-cell lymphoma, peripheral T-cell lymphoma and Burkitt's lymphoma were given a non-Hodgkin's lymphoma, Berlin-FrankfurtMünster-90-based protocol [9] . All of the patients received 6-14 courses of chemotherapy, and the median number of courses was 8.
Follow-up
The follow-up period was estimated from the first day of treatment to either the day of death or the day of the last examination.
Statistical analysis
The Statistical Package for Social Sciences 15.0 (SPSS, Chicago, IL, USA) was used for the statistical analysis. The Mann-Whitney U-test was used to analyse the difference of the period from complete obliteration of the mediastinal mass to the date of a recurrent mediastinal mass and that from the commencement of treatment to the date of a newly developed mediastinal mass, and the difference of the maximal diameters between the recurrent and the newly developed mediastinal masses [10] .
RESULTS
The median follow-up period for the whole study group was 32.9 months (range 10.5-89.4 months). Only 1 child died of tumour metastasis 2 years after completion of chemotherapy, and the remaining 51 children had disease-free survival after treatment until the day of the last examination.
Twenty-three patients were detected with tumour invasion into the mediastinum at initial diagnosis. The clinical and CT findings of these patients are given in Table 2 . The period from complete obliteration of the mediastinal mass to the date of a recurrent mediastinal mass was 1.2-28.2 months, with a median period of 8.6 months. The median maximal diameter of the recurrent masses was 46 mm (ranging from 25 to 60 mm). After 8.7-89.4 months of follow-up, 16 masses (16/23, 70%) shrank naturally, and 7 masses (7/23, 30%) remained unchanged. The follow-up period for the 7 patients with unchanged mediastinal masses was 42.8-89.4 months. Six masses (6/23, 26%) were diffuse and ill-circumscribed, and the remaining 17 masses (17/23, 74%) presented trapezoidal or triangular shapes and were well-circumscribed. Three masses (3/23, 13%) had heterogeneous densities, and the remaining 20 masses (20/23, 87%) had homogeneous densities. All of the masses showed mild enhancement after contrast administration. Seventeen (17/23, 74%) masses slightly displaced, and 6 masses (6/23, 26%) partly surrounded the adjacent vessels ( Fig. 1) .
Twenty-nine patients were detected without tumour invasion into the mediastinum at initial diagnosis. The clinical and CT findings of those patients are given in Table 3 . The period from the treatment commencement date to the date of a newly developed mediastinal mass was 2.7-22.6 months, with a median period of 9.5 months. The median maximal diameter of the newly developed masses was 49 mm (ranging from 30 to 80 mm). After 10.5-73.9 months of follow-up, 26 masses (26/29, 90%) shrank naturally. Three masses (3/29, 10%) remained unchanged, and the follow-up period for these 3 patients with unchanged mediastinal masses was 53.9-73.9 months. Four masses (4/29, 14%) were diffuse and illcircumscribed, and the remaining 25 masses (25/29, 86%) revealed trapezoidal or triangular shapes and were well-circumscribed. Seven (7/29, 24%) and 22 masses (22/29, 76%) had heterogeneous and homogeneous densities, respectively. All of the masses showed mild enhancement after contrast administration. Twenty-five (25/29, 86%) masses slightly displaced, and 4 masses (4/29, 14%) partly surrounded the adjacent vessels (Figs 2 and 3) . The period from complete obliteration of the mediastinal masses to the date of recurrent mediastinal masses and that from commencement of the treatment to the date of newly developed mediastinal masses were not significantly different (P = 0.495). The maximal diameters of the recurrent and newly developed mediastinal masses were not significantly different either (P = 0.091).
DISCUSSION
The thymus gland is known for its variability in size and configuration in both health and disease. In fact, so much variability exists that the true range for normal thymic weight is yet to be established [11] . Reactive thymic hyperplasia in children has been described for a number of conditions, such as recovery from thermal burns [12] , after successful corrective surgery for transposition of the great vessels [13] , cessation of orally administered adrenocorticosteroids [14] and successful completion of therapy for malignancies [11, 15] .
Pathologically, thymic hyperplasia is divided into two types. The first represents an increase in the number of germinal centres and medullary lymphocytes. This type is observed in myasthenia gravis, systemic lupus erythematosus and autoimmune haemolytic anaemia. The second type is caused by overgrowth of normal thymic elements, such as lymphoid cells, reticulum cells and epithelial cells in normal proportions and with normal histological characteristics. The latter type, which is truly a hyperplasia, occurs not only in the cortex and medulla of the thymus but also in the 'extraparenchymal' zone of the thymus, which lies in the anterior mediastinal fat [16] . Reactive thymic hyperplasia pathologically belongs to the second type.
Our study enrolled 52 children with lymphoma who received 6-14 courses of chemotherapy. After 10.5-89.4 months of follow-up, the majority of the children (51/52, 98%) had disease-free survival. Taking into consideration the risk of diagnostic surgical procedures, the recurrent or newly developed masses in the mediastinum 
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during maintenance treatment or follow-up were closely tracked without any intervening measures, and they either atrophied naturally or remained unchanged with long-term observation and follow-up. Finally, these masses were clinically confirmed to be reactive hyperplastic thymus.
For patients with tumour invasion into the mediastinum, our results indicated that the median period from CR of the mediastinal lesions to the date of recurrent mediastinal masses was 8.6 months, which was not significantly different from that of 9.5 months from the commencement of treatment to the date of newly developed mediastinal masses for the patients without tumour invasion into the mediastinum. The literatures reported that reactive thymic hyperplasia occurred 3-12 months after initiation of treatment for malignancies [17] [18] [19] ; our study further specified the interval and indicated that the growth of thymic elements might take 9-10 months.
Our results showed that the maximal diameters of the recurrent and newly developed mediastinal masses were about 50 mm, and the values observed for the 2 patient groups were not significantly different. Some previous studies reported that the maximal diameters of reactive hyperplastic thymus ranged from 22 to 110 mm [18, 19] . Gawande et al. [20] investigated the differentiation of normal thymus from anterior mediastinal lymphoma and lymphoma recurrence on the basis of positron emission tomography; the results showed that more pronounced thymic enlargement occurred with tumour infringement than with thymic rebound or normal thymus. However, it is impossible to define a size threshold for benign and malignant entities due to high inter-individual variations and the characteristic of the decrease in the thymus with increasing age in children [21] [22] [23] .
The analysis of the CT findings for the recurrent and newly developed mediastinal masses showed that all of the cases presented with a single mediastinal mass, 10 (10/52, 19%) of which had diffuse shapes and were ill-circumscribed. The remaining 42 masses (42/52, 81%) presented with trapezoidal or triangular shapes and were well-circumscribed. Forty-two masses (42/52, 81%) had homogeneous densities. All of the masses showed mild enhancement after contrast administration. Forty-two masses (42/ 52, 81%) slightly displaced and 10 masses (10/52, 19%) partly surrounded the adjacent vessels. Above all, with long-term observation and follow-up without any intervening measures, 42 (42/52, 81%) masses shrank naturally, and 10 (10/52, 19%) remained unchanged. We believe that the reasons for these outcomes are as follows. First, pathologically, the reactive thymic hyperplasia belongs to the second type of hyperplasia, and the thymic tissue grows relatively uniformly. Secondly, the masses are not genuine 'tumour', but tumour-like hyperplasia and, thus, do not possess any malignant biological features [24] .
A persistent or new mediastinal mass in a patient undergoing chemotherapy for a malignant disease such as lymphoma causes great concern. Most often, it is believed to indicate recurrent or residual lymphoma. However, such a mass could be evidence of thymic hyperplasia, and it is important to distinguish between these two entities. The characteristic CT findings of lymphoma in the mediastinum include the following: (i) a majority of the tumours are bilateral and extend beyond the anterior mediastinum to the other mediastinal compartments. (ii) The tumour is confluent multi-nodular or lobulated. (iii) The tumour density can be either homogeneous or heterogeneous. In the case of a heterogeneous density, ring, triangle and/or band-like low-density areas, similar to the interspace between fused lymph nodes, are found. (iv) The tumours surround the adjacent vessels. (v) The lesions are always accompanied by cervical and abdominal lymphadenopathy [25] . These findings are helpful for differentiating tumours from thymic hyperplasia.
In summary, reactive thymic hyperplasia can, and often does, occur in children receiving regular chemotherapy for lymphoma, regardless of whether the tumour initially invades the mediastinum. The median period for thymic hyperplasia is 9-10 months, and the median maximal diameter of the hyperplastic thymus is about 50 mm. An overwhelming majority of reactive hyperplastic thymuses have a trapezoidal or triangular shape and are well-circumscribed, with homogeneous density and mild enhancement after contrast administration. The masses also slightly displace adjacent vessels. Most masses shrink naturally with long-term follow-up. Awareness of reactive thymic hyperplasia may help to avoid over-treatment of children with this condition.
